Nasdaq · CIK 0001958777
FBLG FibroBiologics, Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $1.13 on Oct 9, 2026, +80% from the 52-week low and -88% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
FBLGOct 9, 2026 · close 1.13
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at FibroBiologics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Hamid Khoja Chief Scientific Officer buy | $11k 30,000 shares | +96% | +67% from low-73% from high | |
| 43Moderate | Pete O'Heeron CHIEF EXECUTIVE OFFICER buy | $20k 51,500 shares | +1% | +87% from low-70% from high | |
| 58Moderate | Jason Davis Chief Financial Officer buy | $29k 70,000 shares | - | +87% from low-70% from high | |
| 49Moderate | Ruben A Garcia General Counsel buy | $13k 40,000 shares | +29% | +46% from low-76% from high | |
| 30Weak | Ruben A Garcia General Counsel buy | $48k 140,000 shares | - | - | |
| 25Weak | Hamid Khoja Chief Scientific Officer buy | $17k 20,000 shares | +178% | - |
Transactions
The last 24 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Hamid Khoja Chief Scientific Officer | AGrant or award Common Stock | +298,508 | $1.68 | $500k | 301,571 | 27 d ago |
| Sep 15, 2026 | Hamid Khoja Chief Scientific Officer | AGrant or award Warrant (Right to Buy)derivative | +298,508 | - | - | 298,508 | 27 d ago |
| Mar 4, 2026 | Hamid Khoja Chief Scientific Officer | POpen-market purchase Common Stock | +30,000 | $0.38 | $11k | 61,250 | Mar 5, 2026 |
| Mar 2, 2026 | Pete O'Heeron CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +17,428 | $0.35 | $6,152 | 5,924,075 | Mar 4, 2026 |
| Mar 3, 2026 | Pete O'Heeron CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +18,200 | $0.41 | $7,373 | 5,942,275 | Mar 4, 2026 |
| Mar 4, 2026 | Pete O'Heeron CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +15,872 | $0.38 | $6,006 | 5,958,147 | Mar 4, 2026 |
| Mar 2, 2026 | Jason Davis Chief Financial Officer | POpen-market purchase Common Stock | +70,000 | $0.41 | $29k | 70,000 | Mar 3, 2026 |
| Feb 27, 2026 | Ruben A Garcia General Counsel | POpen-market purchase Common Stock | +40,000 | $0.33 | $13k | 180,000 | Mar 2, 2026 |
| Dec 11, 2025 | Ruben A Garcia General Counsel | POpen-market purchase Common Stock | +140,000 | $0.34 | $48k | 140,000 | Dec 12, 2025 |
| Jun 12, 2025 | Matthew Link director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 12, 2025 |
| Jun 12, 2025 | Victoria Ninon Olivia Niklas director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 12, 2025 |
| Jun 12, 2025 | Robert E. Hoffman director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 12, 2025 |
| Jun 12, 2025 | Stacy Ann Coen director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 12, 2025 |
| Jun 12, 2025 | Richard C. Cilento Jr. director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 12, 2025 |
| Jun 9, 2025 | Jason Davis Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Jun 10, 2025 |
| May 27, 2025 | Hamid Khoja Chief Scientific Officer | POpen-market purchase Common Stock | +20,000 | $0.84 | $17k | 31,250 | May 27, 2025 |
| Mar 26, 2025 | Hamid Khoja CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +189,000 | $0.00 | $0 | 189,000 | Mar 28, 2025 |
| Mar 26, 2025 | Ruben A Garcia General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +189,000 | $0.00 | $0 | 189,000 | Mar 28, 2025 |
| Mar 26, 2025 | Pete O'Heeron CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +453,000 | $0.00 | $0 | 453,000 | Mar 28, 2025 |
| Dec 27, 2024 | Ruben A Garcia General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +176,200 | $0.00 | $0 | 176,200 | Dec 30, 2024 |
| Dec 27, 2024 | Hamid Khoja CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +176,200 | $0.00 | $0 | 176,200 | Dec 30, 2024 |
| Dec 27, 2024 | Pete O'Heeron Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +406,339 | $0.00 | $0 | 406,339 | Dec 30, 2024 |
| Dec 9, 2024 | Pete O'Heeron Chief Executive Officer | GGift Common Stock | -100,000 | $0.00 | $0 | 5,906,647 | Dec 9, 2024 |
| Dec 3, 2024 | Pete O'Heeron Chief Executive Officer | GGift Common Stock | -50,000 | $0.00 | $0 | 6,006,647 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Richard C. Cilento Jr.director
- Stacy Ann Coendirector
- Jason DavisChief Financial Officer
- Ruben A GarciaGeneral Counsel
- Robert E. Hoffmandirector, cfo, officer
- Hamid KhojaChief Scientific Officer
- Matthew Linkofficer, director
- Victoria Ninon Olivia Niklasdirector
- Pete O'HeeronCHIEF EXECUTIVE OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.